Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational and interventional studies. The goal of this study was to determine if proxalutamide, an androgen receptor antagonist, could be an effective treatment for men with COVID-19 in an outpatient setting. A randomiz...
Main Authors: | John McCoy, Andy Goren, Flávio Adsuara Cadegiani, Sergio Vaño-Galván, Maja Kovacevic, Mirna Situm, Jerry Shapiro, Rodney Sinclair, Antonella Tosti, Andrija Stanimirovic, Daniel Fonseca, Edinete Dorner, Dirce Costa Onety, Ricardo Ariel Zimerman, Carlos Gustavo Wambier |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.668698/full |
Similar Items
-
Is there a link between androgenetic alopecia and COVID-19?
by: Bartłomiej Zaremba, et al.
Published: (2021-09-01) -
Modern concept of the etiology and pathogenesis of androgenetic alopecia
by: Yuliya Ovcharenko, et al.
Published: (2021-07-01) -
Androgen-associated and androgen-independent causes of alopecia and acne in women. Literature reviewgen-associated and androgen-independent causes of alopecia and acne in women. Literature review
by: І. В. Сідорова, et al.
Published: (2020-05-01) -
Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
by: Eva Estébanez-Perpiñá, et al.
Published: (2021-01-01) -
Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness.
by: Hamada, K., et al.
Published: (2009)